Skip to main content
Home / The International Journal of Tuberculosis and Lung Disease, Volume 16, Number 3

Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs [Short communication]

Buy Article:

$34.78 + tax (Refund Policy)

Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the proportion of rifampicin (RMP) resistant isolates that were isoniazid (INH) susceptible by phenotypic drug susceptibility testing varied widely (0.5–11.6%). RMP-resistant isolates that were INH-susceptible had significantly lower rates of resistance to other first- and second-line anti-tuberculosis drugs (except rifabutin) compared to multidrug-resistant isolates. RMP resistance is not always a good proxy for a presumptive diagnosis of multidrug-resistant TB, which has implications for use of molecular assays that identify only RMP resistance-associated DNA mutations.

Keywords: drug resistance; molecular diagnostic tests; rifampicin resistance; tuberculosis

Document Type: Research Article

Affiliations: 1: Centers for Disease Control and Prevention, Atlanta, Georgia, USA 2: Division of General Internal Medicine, Albert Einstein College of Medicine, Bronx, New York, USA 3: World Health Organization, Geneva, Switzerland 4: Korean Institute of Tuberculosis, Seoul, Republic of Korea 5: Institute of Tropical Medicine, Antwerp, Belgium 6: National Institute of Infectious Diseases, Buenos Aires, Argentina 7: Institut Pasteur d'Algérie, Algiers, Algeria 8: National Reference Center for Mycobacteria, Borstel, Germany 9: Hospital Universitaris Vall d'Hebron, Barcelona, Spain 10: Institute of Public Health of Chile, Providencia Santiago, Santiago, Chile 11: National Institute of Public Health, Scrobarova, Czech Republic 12: Health Protection Agency, London, UK 13: National Institute of Health, Porto, Portugal 14: Queensland Mycobacterium Reference Laboratory, Brisbane, Queensland, Australia 15: Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia

Publication date: 01 March 2012

More about this publication?

  • The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.

    The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content